Top pharma CEO says Covid likely to become endemic, urges investment in pandemic preparedness

Top pharma CEO says Covid likely to become endemic, urges investment in pandemic preparedness


Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines.

Bloomberg | Bloomberg | Getty Images

The chief executive of Swiss pharmaceutical giant Novartis on Thursday warned the coronavirus pandemic will likely settle into an endemic phase and renewed calls for policymakers to sufficiently finance pandemic preparedness.

“If you look over the last two years, we have populations that have built up immunity, you have a virus that’s continuing to make shifts, but I think what we’re going to settle into is more of an endemic environment with respect to coronaviruses and the Covid virus specifically,” Vas Narasimhan, CEO of Novartis, told CNBC at the World Economic Forum in Davos, Switzerland.

“That will mean we will have sporadic outbreaks, we will have populations at risk that need to continue to be vaccinated but I would expect as it has been the case with other coronaviruses over the last centuries that the human populations will adapt and will come to a kind of resolution with this virus.”

Narasimhan, who has previously warned that future pandemics are bound to happen, made clear that world leaders must learn from the coronavirus crisis to be in a better place for future pandemics.

“I think what is really important now is we turn our attention to pandemic preparedness for the future,” Narasimhan said.

'We have reached an endemic environment with Covid,' says Novartis CEO

“I’m not sure we have learned our lessons of the past that we need to invest in [research and development], we need to invest more in preparedness to be ready for the next pandemic — and I think that should be on the global agenda,” he added.

‘Straining credulity’

His comments come shortly after U.N. Secretary-General Antonio Guterres warned the world’s failure to prepare for future pandemics is “straining credulity.”

Speaking at WEF on Wednesday, Guterres said, “Somehow — after all we have endured — we have not learned the global public health lessons of the pandemic. We are nowhere near ready for pandemics to come.”

Last month, China abruptly ended most Covid-19 controls, leading to a surge in infections among the population of 1.4 billion.

Beijing reported on Saturday that almost 60,000 people with Covid had died in hospital since the country dropped its strict Covid restrictions last month, a sharp increase from previous figures.

Asked whether it makes pharmacological sense for some governments to take a tough line on the entry of Chinese citizens into their country following Beijing’s reopening, Narasimhan replied, “I think from an epidemiological standpoint, you can certainly call it into question because in the end, we’ve learned the hard way these viruses will move regardless, and they don’t really pay attention to national borders.”

“I continue to believe open borders and open economies are the right solution for the global order,” he added.



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More